Literature DB >> 33439824

The Management of Non-Dialysis-Dependent Chronic Kidney Disease in Primary Care.

Gesine Weckmann1, Jean-François Chenot, Sylvia Stracke.   

Abstract

BACKGROUND: Approximately 10% of adults in Germany have chronic kidney disease (CKD). The prevalence of CKD among patients being cared for by general practitioners is approximately 30%, and its prevalence in nursing homes is over 50%. An S3 guideline has been developed for the management of CKD in primary care.
METHODS: The guideline is based on publications retrieved by a systematic search of the literature for international guidelines published in the period 2013-2017, and additional searches on specific questions. It was created by the German College of General Practitioners and Family Physicians (Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin, DEGAM) and consented with the German Societies of Nephrology and Internal Medicine (DGfN, DGIM) and patient representation.
RESULTS: Upon the initial diagnosis of CKD (glomerular filtration rate [GFR] <60 mL/ min), the patient's blood pressure and urinary albumin-to-creatinine ratio (ACR) should be measured, and the urine should be examined for hematuria. Monitoring intervals are determined on an individual basis depending on the stage of disease and the patient's general state of health and personal preferences. Nephrological consultation should be obtained if the GFR is less than 30 mL/min, if CKD is initially diagnosed (GFR 30-59 mL/min) in the presence of persistent hematuria without any urological explanation or of albinuria in stage A2 or higher, if the patient has refractory hypertension requiring three or more antihypertensive drugs, or if the renal disease is rapidly progressive. The threshold for referring a patient should be kept low for persons under age 50; persons over age 70 should be referred only if warranted in consideration of their comorbidities and individual health goals.
CONCLUSION: The main elements of the treatment of CKD are the treatment of hypertension and diabetes and the modification of lifestyle factors. An innovation from the primary care practioner's perspective is the assessment of albuminuria with the albumin-to-creatinine ratio.

Entities:  

Mesh:

Year:  2020        PMID: 33439824      PMCID: PMC7878722          DOI: 10.3238/arztebl.2020.0745

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  21 in total

1.  CKD Prevalence Varies across the European General Population.

Authors:  Katharina Brück; Vianda S Stel; Giovanni Gambaro; Stein Hallan; Henry Völzke; Johan Ärnlöv; Mika Kastarinen; Idris Guessous; José Vinhas; Bénédicte Stengel; Hermann Brenner; Jerzy Chudek; Solfrid Romundstad; Charles Tomson; Alfonso Otero Gonzalez; Aminu K Bello; Jean Ferrieres; Luigi Palmieri; Gemma Browne; Vincenzo Capuano; Wim Van Biesen; Carmine Zoccali; Ron Gansevoort; Gerjan Navis; Dietrich Rothenbacher; Pietro Manuel Ferraro; Dorothea Nitsch; Christoph Wanner; Kitty J Jager
Journal:  J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 10.121

2.  Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study.

Authors:  Gerd Assmann; Paul Cullen; Helmut Schulte
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

3.  Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016.

Authors:  Yan Xie; Benjamin Bowe; Ali H Mokdad; Hong Xian; Yan Yan; Tingting Li; Geetha Maddukuri; Cheng-You Tsai; Tasheia Floyd; Ziyad Al-Aly
Journal:  Kidney Int       Date:  2018-08-03       Impact factor: 10.612

4.  Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-10-16       Impact factor: 25.391

5.  Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease.

Authors:  Jing Chen; Matthew J Budoff; Muredach P Reilly; Wei Yang; Sylvia E Rosas; Mahboob Rahman; Xiaoming Zhang; Jason A Roy; Eva Lustigova; Lisa Nessel; Virginia Ford; Dominic Raj; Anna C Porter; Elsayed Z Soliman; Jackson T Wright; Myles Wolf; Jiang He
Journal:  JAMA Cardiol       Date:  2017-06-01       Impact factor: 14.676

Review 6.  Altered dietary salt intake for people with chronic kidney disease.

Authors:  Emma J McMahon; Katrina L Campbell; Judith D Bauer; David W Mudge
Journal:  Cochrane Database Syst Rev       Date:  2015-02-18

Review 7.  The Investigation of Hematuria.

Authors:  Christian Bolenz; Bernd Schröppel; Andreas Eisenhardt; Bernd J Schmitz-Dräger; Marc-Oliver Grimm
Journal:  Dtsch Arztebl Int       Date:  2018-11-30       Impact factor: 5.594

8.  Evaluation of a recalibrated Systematic Coronary Risk Evaluation cardiovascular risk chart: results from Systematic Coronary Risk Evaluation Germany.

Authors:  Hans-Werner Hense; Eva Koesters; Jürgen Wellmann; Christa Meisinger; Henry Völzke; Ulrich Keil
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2008-08

9.  The Prevalence of Renal Failure. Results from the German Health Interview and Examination Survey for Adults, 2008-2011 (DEGS1).

Authors:  Matthias Girndt; Pietro Trocchi; Christa Scheidt-Nave; Silke Markau; Andreas Stang
Journal:  Dtsch Arztebl Int       Date:  2016-02-12       Impact factor: 5.594

10.  Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines.

Authors:  Gesine F C Weckmann; Sylvia Stracke; Annekathrin Haase; Jacob Spallek; Fabian Ludwig; Aniela Angelow; Jetske M Emmelkamp; Maria Mahner; Jean-François Chenot
Journal:  BMC Nephrol       Date:  2018-10-11       Impact factor: 2.388

View more
  1 in total

Review 1.  [Long-term physical and psychological consequences of chronic kidney disease].

Authors:  Friedrich Thaiss
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-03-21       Impact factor: 1.513

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.